霍德義 教授

Teh-Ia Huo Professor

 

Professor

霍德義 教授 

Address: Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, 201, Sec. 2, Shih-Pai Rd, Taipei, Taiwan

 

E-mail: tihuo@vghtpe.gov.tw

 

 


 

Currently in office:

Professor, Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan

Attending physician, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

 

Membership in Medical Societies:

Member, Chinese Medical Association, Republic of China

Member, Taipei Physician's Association, Republic of China

Member, The Digestive Endoscopy Society of the Republic of China

Member, The Society of Internal Medicine, Republic of China

Member, Gastroenterological Society of Taiwan

Member, Taiwan Association for the Study of the Liver

 

Deputy Editor:

Journal of the Chinese Medical Association

 

Editorial Board:

Journal of Gastroenterology and Hepatology

 


Publications:

(* indicates corresponding author)

1.     Teh-Ia Huo, Jaw-Ching Wu, Chung-Ru Lai, Ching-Liang Lu, Wen-Yung Sheng, Shou-Dong Lee. Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. J Hepatol 1996;25:439-44.

2.     Teh-Ia Huo, Jaw-Ching Wu, Wen-Yung Sheng, Cho-Yu Chan, Shinn-Jang Hwang, Trong-Zong Chen, Shou-Dong Lee. Prognostic factor analysis of fulminant and subfulminant hepatic failure in an area endemic for hepatitis B. J Gastroenterol Hepatol 1996;11:560-5.

3.     Teh-Ia Huo, Jaw-Ching Wu, Chang-Fang Chiu, Shou-Dong Lee. Severe hyperbilirubinemia due to acute hepatitis A superimposed on a chronic hepatitis B carrier with glucose-6-phosphate dehydrogenase deficiency. Am J Gastroenterol 1996;91:158-9

4.     Teh-Ia Huo, Jaw-Ching Wu, Ruey-Yi Lin, Wen-Yung Sheng, Full-Young Chang, Shou-Dong Lee. Decreasing hepatitis D virus infection in Taiwan: An analysis of contributory factors. J Gastroenterol Hepatol 1997;12:747-51. (with an editorial)

5.     Teh-Ia Huo, Jaw-Ching Wu, Pui-Ching Lee, Gar-Yang Chau, Wing-Yiu Lui, Shyh-Haw Tsay, Ling-Tan Ting, Full-Young Chang, Shou-Dong Lee. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998;28:231-6. (with an editorial)

6.     Teh-Ia Huo, Jaw-Ching Wu, Yi-Hsiang Huang, Ueng-Cheng Yang, I-Jane Sheen, Full-Young Chang, Shou-Dong Lee. Evidence of transmission of hepatitis B virus to spouses from sequence analysis of the viral genome. J Gastroenterol Hepatol 1998;13:1138-42.

7.     Teh-Ia Huo, Jaw-Ching Wu, Pui-Ching Lee, Shyh-Haw Tsay, Full-Young Chang, Shou-Dong Lee. Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection. J Clin Gastroenterol 2000;30:250-4. (with an editorial)

8.     Teh-Ia Huo, Jaw-Ching Wu, Shinn-Jang Hwang, Chung-Ru Lai, Pui-Ching Lee, Shyh-Haw Tsay, Full-Young Chang, Shou-Dong Lee. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol 2000;12:687-93.

9.     Teh-Ia Huo, Wu-Chang Yang, Jaw-Ching Wu, Kuang-Liang King, Ching-Yuang Lin, Che-Chuan Loong, Wing-Yiu Lui, Full-Young Chang, Shou-Dong Lee. Long-term outcome of kidney transplantation in patients with hepatitis C virus infection. Hepato-Gastroenterology 2001;48:169-73.

10. Teh-Ia Huo, Wu-Chang Yang, Jaw-Ching Wu, Kuang-Liang King, Che-Chuan Loong, Ching-Yuang Lin, Full-Young Chang, Shou-Dong Lee. Kidney transplantation in patients with chronic hepatitis B virus infection: is the prognosis worse? Dig Dis Sci 2001;46:469-75.

11. Teh-Ia Huo, Xin Wang, Marshonna Forgues, Chuan-Ging Wu, Elisa Spillare, Carlo Giannini, Christian Brechot, Curtis Harris. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene 2001;20:3620-8.

12. Teh-Ia Huo, Yi-Hsiang Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Survival benefit of cirrhotic patients with hepatocellular carcinoma treated by percutaneous ethanol injection as a salvage therapy. Scand J Gastroenterol 2002;37:350-5.

13. Teh-Ia Huo, Yi-Hsiang Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scand J Gastroenterol 2003;38:770-8.

14. Teh-Ia Huo, Jaw-Ching Wu, Shou-Dong Lee. Outcomes of patients with seroclearance of HBsAg: different facets of a truth. Gastroenterology 2003;125:274-5.

15. Teh-Ia Huo, Shou-Dong Lee, Jaw-Ching Wu. Screening for hepatocellular carcinoma in high-risk patients: western versus eastern virus. Hepatology 2003;38: 269.

16. Teh-Ia Huo, Wing-Yiu Lui, Yi-Hsiang Huang, Gar-Yang Chau, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol 2003;98:2293-8.

17. Teh-Ia Huo, Jaw-Ching Wu, Wing-Yiu Lui, Pui-Ching Lee, Yi-Hsiang Huang, Gar-Yang Chau, Shyh-Haw Tsay, Full-Young Chang, Shou-Dong Lee. Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. Eur J Gastroenterol Hepatol 2003;15:1203-8.

18. Teh-Ia Huo, Yi-Hsiang Huang, Jaw-Ching Wu, Jen-Huei Chiang, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. Ann Oncol 2003;14:1648-53.

19. Teh-Ia Huo, Jaw-Ching Wu, Shiow-Ing Wu, An-Lung Chang, Shih-Ku Lin, Chun-Hung Pan, Yi-Hsiang Huang, Full-Young Chang, Shou-Dong Lee. Changing seroepidemiology of hepatitis B, C and D virus infections in high-risk populations. J Med Virol 2004;72:41-5.

20. Teh-Ia Huo, Jaw-Ching Wu, Wing-Yiu Lui, Rheun-Chuan Lee, Che-Chuan Loong, Yi-Hsiang Huang, Shyh-Haw Tsay, Full-Young Chang, Shou-Dong Lee. Reliability of the contemporary radiology to measure tumor size of hepatocellular carcinoma in patients undergoing resection: limitations and clinical implications. Scand J Gastroenterol 2004;39:46-52.

21. Teh-Ia Huo, Jaw-Ching Wu, Yi-Hsiang Huang, Wing-Yu Lui, Jen-Huei Chiang, Pui-Ching Lee, Shyh-Haw Tsay, Full-Young Chang, Shou-Dong Lee. Selective prognostic impact of serum -fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol Rep 2004;11:543-50.

22. Teh-Ia Huo, Yi-Hsiang Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Percutaneous injection therapy for hepatocellular carcinoma in patients with chronic renal insufficiency. Eur J Gastroenterol Hepatol 2004;16:325-31.

23. Teh-Ia Huo, Jaw-Ching Wu, Wing-Yiu Lui, Yi-Hsiang Huang, Pui-Ching Lee, Jen-Huei Chiang, Full-Young Chang, Shou-Dong Lee. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and non-surgical treatment. Am J Gastroenterol 2004;99:1479-87. (with an editorial)

24. Teh-Ia Huo, Yi-Hsiang Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Persistent retention of acetic acid is associated with complete tumor necrosis in patients with hepatocellular carcinoma undergoing percutaneous acetic acid injection. Scand J Gastroenterol 2004;39:168-73.

25. Teh-Ia Huo, Wing-Yiu Lui, Jaw-Ching Wu, Yi-Hsiang Huang, Kuang-Liang King, Che-Chuan Loong, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors and association with intrahepatic tumor recurrence. World J Surg 2004;28:258-62.

26. Teh-Ia Huo, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 2004;24:210-5.

27. Teh-Ia Huo, Jaw-Ching Wu. Does antibody to hepatitis B surface antigen protect renal transplant patients from hepatitis B? J Gastroenterol Hepatol 2004;19:841-3.

28. Teh-Ia Huo, Jaw-Ching Wu, Cheng-Yuan Hsia, Gar-Yang Chau, Wing-Yiu Lui, Yi-Hsiang Huang, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Hepatitis C virus infection is a risk factor of tumor recurrence after resection for small hepatocellular carcinoma. World J Surg 2004;28:787-91.

29. Teh-Ia Huo, Yi-Hsiang Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study. Ann Oncol 2004;15:775-80.

30. Teh-Ia Huo, Shou-Dong Lee, Jaw-Ching Wu. Staging for hepatocellular carcinoma: look for a perfect classification system. J Hepatol 2004;40:1041-2.

31. Teh-Ia Huo, Shou-Dong Lee, Jaw-Ching Wu. Is diabetes a risk factor for hepatocellular carcinoma? Gastroenterology 2004;127:360-1.

32. Teh-Ia Huo, Jaw-Ching Wu, Yi-Hsiang Huang, Jen-Huei Chiang, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Acute renal failure after transarterial chemoemboilzation for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Aliment Pharmacol Ther 2004;19:999-1007.

33. Teh-Ia Huo, Jaw-Ching Wu, Shou-Dong Lee. Long-term outcome of hepatitis C virus superinfection in HBsAg carriers. Gastroenterology 2004;127;690.

34. Teh-Ia Huo, Yi-Hsiang Huang, Jaw-Ching Wu, Jen-Huei Chiang, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey. Aliment Pharmacol Ther 2004;19:1391-8.

35. Teh-Ia Huo, Jaw-Ching Wu, Han-Chieh Lin, Fa-Yauh Lee, Ming-Chih Hou, Yi-Hsiang Huang, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transplant 2004;10:1507-13.

36. Teh-Ia Huo, Jaw-Ching Wu, Sou-Dong Lee. Contrast medium-associated renal dysfunction in patients with cirrhosis. Hepatology 2004;40:1474.

37. Teh-Ia Huo, Shou-Dong Lee. Management of inoperable hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:S272-S278.

38. Teh-Ia Huo, Jaw-Ching Wu, Han-Chieh Lin, Fa-Yauh Lee, Ming-Chih Hou, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Evaluation of the increase in model for end-stage liver disease (MELD) score over time as a prognostic predictor in patients with advanced liver cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 2005;42: 826-32. (with an editorial)

39. Teh-Ia Huo, Yi-Hsiang Huang. Staging for hepatocellular carcinoma: treatment strategy matters. Hepatology 2005;41:678.

40. Teh-Ia Huo, Shou-Dong Lee, Jaw-Ching Wu. Ethanol injection versus radiofrequency ablation for hepatocellular carcinoma: which is better? Gastroenterology 2005;128:806-7.

41. Teh-Ia Huo, Jaw-Ching Wu, Shou-Dong Lee. MELD in liver transplantation: the da Vinci code for the Holy Grail? J Hepatol 2005;42:474-5.

42. Teh-Ia Huo, Jaw-Ching Wu, Shou-Dong Lee. Are alcohol, tobacco and obesity genuine risk factors for hepatocellular carcinoma? J Hepatol 2005;42:941.

43. Teh-Ia Huo, Shou-Dong Lee, Jaw-Ching Wu. Which is the holy grail in liver transplantation, hyponatremia, MELD or combination? Liver Transplant 2005; 11:710.

44. Teh-Ia Huo, Yi-Hsiang Huang, Shou-Dong Lee, Jaw-Ching Wu. Is there an ideal prognostic model for hepatocellular carcinoma? Gut 2005;54:1348.

45. Teh-Ia Huo, Shou-Dong Lee, Jaw-Ching Wu. Risk factor analysis for cholangiocarcinoma: limitations of cross-sectional study. Gastroenterology 2005;129:395.

46. Teh-Ia Huo, Jaw-Ching Wu, Shou-Dong Lee. Comparison of staging systems for HCC: one more positive answer or mission impossible? Hepatology 2005;42:238-9.

47. Teh-Ia Huo, Han-Chieh Lin, Shou-Dong Lee. Liver transplantation is a time dependent prognostic predictor in cirrhotic patients with esophageal varices. Gastroenterology 2005;129:769-70.

48. Teh-Ia Huo, Jaw-Ching Wu, Han-Chieh Lin, Fa-Yauh Lee, Ming-Chih Hou, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Different model for end-stage liver disease score block distributions may have a variable ability for outcome prediction in cirrhotic patients. Transplantation 2005;80:1414-8.

49. Teh-Ia Huo, Han-Chieh Lin, Fa-Yauh Lee, Ming-Chih Hou, Pui-Ching Lee, Jaw-Ching Wu, Full-Young Chang, Shou-Dong Lee. Occurrence of cirrhosis-related complications is a time dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver Int 2006;26:55-61.

50. Teh-Ia Huo, Han-Chieh Lin, Jaw-Ching Wu, Fa-Yauh Lee, Ming-Chih Hou, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transplant 2006;12:65-71.

51. Teh-Ia Huo, Ming-Chih Hou, Han-Chieh Lin, Jaw-Ching Wu, Fa-Yauh Lee, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications. Clin Transplant 2006;20:188-94.

52. Teh-Ia Huo, Yi-Hsiang Huang, Han-Chieh Lin, Jaw-Ching Wu, Jen-Huei Chiang, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 2006;101:975-82.

53. Teh-Ia Huo, Shou-Dong Lee, Jaw-Ching Wu. Do baseline ALT levels predict complications of chronic hepatitis B? Gut 2006;55:745.

54. Teh-Ia Huo, Han-Chieh Lin, Yi-Hsiang Huang, Jaw-Ching Wu, Jen-Huei Chiang, Pui-Ching Lee, Shou-Dong Lee. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing loco-regional therapy. Cancer 2006;107:141-8.

55. Teh-Ia Huo, Shou-Dong Lee, Jaw-Ching Wu. Hepatitis after arterial embolization for hepatocellular carcinoma: viral reactivation or ischemia? Hepatology 2006:43:1400-1.

56. Teh-Ia Huo, Pui-Ching Lee, Yi-Hsiang Huang, Jaw-Ching Wu, Han-Chieh Lin, Jen-Huei Chiang, Full-Young Chang, Shou-Dong Lee. The sequential changes of the model for end-stage liver disease score correlate with the severity of liver cirrhosis in patients with hepatocellular carcinoma undergoing loco-regional therapy. J Clin Gastroenterol 2006;40:543-50.

57. Teh-Ia Huo, Yi-Hsiang Huang, Hui-Chun Huang, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee. Fever and infectious complications after percutaneous acetic acid injection therapy for hepatocellular carcinoma: incidence and risk factor analysis. J Clin Gastroenterol 2006:60:639-42.

58. Teh-Ia Huo, Shou-Dong Lee, Jaw-Ching Wu. Role of loco-regional therapy for hepatocellular carcinoma before liver transplantation: answer or myth? Liver Transplant 2006;12:1560.

59. Teh-Ia Huo, Shou-Dong Lee. Role of the model for end-stage liver disease and serum -fetoprotein as prognostic predictors for hepatocellular carcinoma. Liver Int 2006;26:1300-1.

60. Cheng-Yuan Hsia,Teh-Ia Huo, Shu-Yuan Chiang, Ming-Fong Lu, Chia-Lu Sun, Jaw-Ching Wu, Pui-Ching Lee, Chin-Wen Chi, Wing-Yiu Lu, Shou-Dong Lee. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 2007;33:208-12.

61. Teh-Ia Huo, Yi-Hsiang Huang, Jen-Huei Chiang, Jaw-Ching Wu, Pui-Ching Lee, Chin-Wen Chi, Shou-Dong Lee. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing loco-regional therapy: Is there a lead-time bias? Scand J Gastroenterol 2007;42:485-92.

62. Teh-Ia Huo, Ying-Wen Wang, Ying-Ying Yang, Han-Chieh Lin, Pui-Ching Lee, Ming-Chih Hou, Fa-Yauh Lee, Shou-Dong Lee. The model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int 2007;27:498-506. (with an editorial)

63. Teh-Ia Huo, Cheng-Yuan Hsia, Chi-Jen Chu, Yi-Hsiang Huang, Wing-Yiu Lui, Jaw-Ching Wu, Pui-Ching Lee, Chin-Wen Chi, Shou-Dong Lee. The predictive ability of serum -fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance. J Surg Oncol 2007 15;95:645-5.

64. Ying-Wen Wang, Teh-Ia Huo (equal contribution as the first author), Ying-Ying Yang, Ming-Chih Hou, Pui-Ching Lee, Han-Chieh Lin, Fa-Yauh Lee, Chin-Wen Chi, Shou-Dong-Lee. Correlation and comparison of the model for end-stage liver disease, portal pressure and serum sodium for outcome prediction in patients with liver cirrhosis. J Clin Gastroenterol 2007;41:706-12. (with an editorial)

65. Teh-Ia Huo, Han-Chieh Lin, Cheng-Yuan Hsia, Pui-Ching Lee, Jaw-Ching Wu, Chin-Wen Chi, Shou-Dong Lee. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 2007;102:1920-30.

66. Teh-Ia Huo, Jaw-Ching Wu, Shou-Dong Lee. Does hepatitis B viral load determine the outcome of patients with hepatocellular carcinoma undergoing chemotherapy? Hepatology 2007;46:1665-6.

67. Teh-Ia Huo, Han-Chieh Lin, Shou-Dong Lee. To MELD or not to MELD, that is a question. Liver Transpl 2007;13:1618.

68. Samantha Huo, Teh-Ia Huo, Han-Chieh Lin, Chin-Wen Chi, Pui-Ching Lee, Fan-Wei Tseng, Shou-Dong Lee. Is the corrected-creatinine MELD a feasible strategy to adjust gender difference in organ allocation for liver transplantation? Transplantation 2007;84:1406-12.

69. Teh-Ia Huo, Shou-Dong Lee, Han-Chieh Lin. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int 2008;28: 606-13.

70. Teh-Ia Huo, Han-Chieh Lin, Samantha C. Huo, Pui-Ching Lee, Jaw-Ching Wu, Fa-Yauh Lee, Ming-Chih Hou, Shou-Dong Lee. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis. Liver Transpl 2008; 14: 837-44.

71. Teh-Ia Huo, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Jen-Huei Chiang, Yi-You Chiou, Samantha C. Huo, Pui-Ching Lee, Shou-Dong Lee. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma (HCC) undergoing locoregional therapy. Clin Transplant 2008;22: 469-75.

72. Teh-Ia Huo, Han-Chieh Lin. Metastatic hepatocelliular carcinoma: when, how, where and so what? Liver Int 2008;28:1183-5.

73. Teh-Ia Huo, Han-Chieh Lin, Cheng-Yuan Hsia, Yi-Hsiang Huang, Jaw-Ching Wu, Jen-Huei Chiang, Yi-You Chiou, Wing-Yiu Lui, Pui-Ching Lee, Shou-Dong Lee. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis 2008;40:882-9.

74. Teh-Ia Huo, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su, Han-Chieh Lin, Chia-Yang Hsu, Pui-Ching Lee, Wing-Yiu Lui, Che-Chuan Loong, Jen-Huei Chiang, Yi-You Chiou, Shou-Dong Lee. Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection? Liver Int 2009; 29:767-73.

75. Teh-Ia Huo, Cheng-Yuan Hsia, Yi-Hsiang Huang, Han-Chieh Lin, Pui-Ching Lee, Wing-Yiu Lui, Jen-Huei Chiang, Yi-You Chiou, Che-Chuan Loong, Shou-Dong Lee. Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium and five cancer staging systems. J Clin Gastroenterol 2009;43:773-81. (with an editorial)

76. Hui-Chun Huang, Fa-Yauh Lee, Teh-Ia Huo. Complications of cirrhosis: major adverse events, pre-transplant assessment and outcome prediction. J Gastroenterol Hepatol 2009 (in press)

77. Chia-Yang Hsu, Han-Chieh Lin, Yi-Hsiang Huang, Chien-Wei Su, Fa-Yauh Lee, Teh-Ia Huo, Pui-Ching Lee, Jing-Yi Lee, Shou-Dong Lee. Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Dig Liver Dis 2009 (in press)

78. Teh-Ia Huo, Chia-Yang Hsu, Han-Chieh Lin, Pui-Ching Lee, Jing-Yi Lee, Fa-Yauh Lee, Ming-Chih Hou, Shou-Dong Lee. Selecting an optimal cutoff value for creatinine in the model for end-stage liver disease equation. Clin Transplant 2009 (in press)

79. Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Jen-Huey Chiang, Pui-Ching Lee, Fa-Yauh Lee, Teh-Ia Huo, Shou-Dong Lee. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int 2010 (in press)

80. Teh-Ia Huo, Chia-Yang Hsu, Yi-Hsiang Huang, Cheng-Yuan Hsia, Han-Chieh Lin, Pui-Ching Lee, Che-Chuan Loong, Jen-Huey Chiang, Yi-You Chiou, Shou-Dong Lee. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 2010 (in press)

81. Chia-Yang Hsu, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su, Han-Chieh Lin, Pui-Ching Lee, Che-Chuan Loong, Jen-Huei Chiang, Teh-Ia Huo, Shou-Dong Lee. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010 (in press)

 

藥理所首頁